- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
IntraLase femtosecond laser approved for sale in Taiwan market
The IntraLase femtosecond laser (IntraLase Corp.) has been approved for sale in Taiwan. Taiwan Hwa-In, IntraLase’s distributor in Hong Kong and Mainland China, will offer the company’s products immediately.
The IntraLase femtosecond laser (IntraLase Corp.) has been approved for sale in Taiwan. Taiwan Hwa-In, IntraLase’s distributor in Hong Kong and Mainland China, will offer the company’s products immediately.
“The added safety of the IntraLase Method in LASIK will provide excellent momentum to drive patient demand in Taiwan, which has a very large number of patients seeking safer and more reliable treatments,” said Jay Hsu, chief executive officer (CEO) of Taiwan Hwa-In.
IntraLase President and CEO Robert J. Palmisano added, “The Taiwanese market represents an exciting opportunity and further demonstrates the global potential of IntraLase technology. We look forward to entering the market and helping Taiwanese practitioners offer clinically proven safety and improved visual outcomes to their patients.”
